尼洛替尼与达沙替尼差异.pptxVIP

For internal use only. Not to be shown, distributed or discussed with anyone outside Novartis. 1 Differentiation For internal use only. Not to be shown, distributed or discussed with anyone outside Novartis. T A S 1 4 1 1 2 4 2 0 4 1 • 作用机理 • ENESTnd DASISION • 安全性和合并症区隔 For internal use only. Not to be shown, distributed or discussed with anyone outside Novartis. 目 录 TAS141124204 2 作用机理区隔 For internal use only. Not to be shown, distributed or discussed with anyone outside Novartis. T A S 1 4 1 1 2 4 2 0 4 3 • 目前公认 Ph+ CML是一种“单一靶点疾病 ” • Bcr-Abl是Ph+ CML的确切病因和关键驱动因素 • 在